Overview

• Biopharmaceutical company founded in 2000 and located in West Conshohocken, Pennsylvania
• Focused on developing novel therapeutics for nonalcoholic steatohepatitis (NASH)
• Received FDA accelerated approval for NASH treatment in adults with moderate to advanced liver fibrosis
• Currently conducting Phase 3 clinical trial for NASH treatment with compensated cirrhosis
• Small company with 10 employees specializing in clinical research and pharmaceutical development

Specializations

• Clinical Research focused on metabolic liver disease treatments
• Pharmaceutical development targeting nonalcoholic steatohepatitis (NASH)
• Biotechnology research in liver fibrosis therapeutic interventions
• Advanced stage drug development with FDA regulatory engagement

Services & Approach

• Development of targeted therapeutic treatments for NASH
• Clinical trial management for liver disease pharmaceutical interventions
• FDA regulatory approval process navigation for novel pharmaceutical compounds
• Precision medical research in metabolic liver dysfunction treatments